| Purity: | 99% |
|---|---|
| Model Number: | 84371-65-3 |
| Brand Name: | NJBN STEROID |
| Grade Standard: | Medicine Grade |
| Type: | TRENBOLONE SERIES |
| Place of Origin: | China (Mainland) |
| EINECS No.: | 84371-65-3 |
| MF: | C29H35NO2 |
| Other Names: | 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-9-dien-3 |
| CAS No.: | 84371-65-3 |
| MW: | 429.59 |
| Sample: | Free |
Quick Details
Specifications
Mifepristone Progesterone Receptor Antagonist CAS: 84371-65-3 99%
______________________________________________________________________________________________________
Basic info:
Product Name: Mifepristone
Synonyms: 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-9-dien-3-one; 11beta-[4-(n, n-dimethylamino)phenyl]-17alpha-(prop-1-ynyl)-delta4,9-estradiene; 17-beta)-(11-bet; 17beta)-11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl)estra-(11bet; 17-beta-hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oest; -17beta-ol-3-one; 4,9-dien-3-one; r38486
CAS: 84371-65-3
MF: C29H35NO2
MW: 429.59
Usage: A progesterone receptor antagonist with partial agonist activity. Abortifacient.
Usage: glutamate uptake inhibitor, AMPA blocker
______________________________________________________________________________________________________
Mifepristone
It is a novel anti-progestin and has anti-glucocorticoid activity without the activity of progesterone, estrogen, androgen and anti-estrogen. It has a progesterone receptor affinity five times as high as progesterone. It is used for anti-pregnancy, inducing menstruation and terminating pregnancy, intrauterine inducer labor for dead fetal.
______________________________________________________________________________________________________
Mifepristone
Oral administration has anti-pregnancy effect, currently applied for people with pregnancy < 49 days. Specific usage in three:
The first usage: orally administration of 600 mg mifepristone in single dose, place 1mg PGF2α (Kaposi prostaglandin) or PGO5 (Kaposi prostaglandin methyl ester) at the vaginal fornix at third or fourth day with the complete abortion rate being as high as 92.3 %. Currently Mifepristone dose has been reduced to a single dose of 200mg, or divided doses of 125-150mg with clinical results not being affected.
The second usage: oral administration of single dose of 600 mg; apply intramuscular injection 0.25 mg of a single oral dose; at 36-48 hours after oral administration, apply intramuscular injection 0.25 mg, or 0.375 mg or 0.5 mg of sulprostone with complete abortion rate of 96%; with the larger amount of sulprostone applied, the sooner the embryonic will be discharged.
The third usage: apply a single oral-administrated dose of 600mg; at 48 hours after oral administration, place 1 mg of ONO802 (gemeprost) pessary suppository inside of the vagina with the complete abortion rate being 95%.
For people with amenorrhea longer than seven weeks, orally administrate 100 mg of mifepristone each time with 2 times per day, and continue for 4 days. You can also apply 1 mg of Kaposi forefront methyl suppository for vagina at 36 to 48 hours after treatment. Have rest in bed for 2 hours and clinic observation for 6 hours. Pay attention to the condition of bleeding after medication to check whether there are pregnancy products being discharged and any adverse reactions.
For labor induction of middle and late dead fetal, take 200 mg each time and 2 times daily. Consecutively take for two days for inducing menstruation and terminating pregnancy. During the 23 to 26 days at menstrual cycle, take 100 ~ 200mg each time with once daily. Consecutively take four days.
______________________________________________________________________________________________________
Basic info:
Product Name: Mifepristone
Synonyms: 11-(4-(dimethylamino)phenyl)-17-hydroxy-17-(1-propynyl)-estra-9-dien-3-one; 11beta-[4-(n, n-dimethylamino)phenyl]-17alpha-(prop-1-ynyl)-delta4,9-estradiene; 17-beta)-(11-bet; 17beta)-11-[4-(dimethylamino)-phenyl]-17-hydroxy-17-(1-propynyl)estra-(11bet; 17-beta-hydroxy-11-beta-(4-dimethylaminophenyl-1)-17-alpha-(prop-1-ynyl)oest; -17beta-ol-3-one; 4,9-dien-3-one; r38486
CAS: 84371-65-3
MF: C29H35NO2
MW: 429.59
Usage: A progesterone receptor antagonist with partial agonist activity. Abortifacient.
Usage: glutamate uptake inhibitor, AMPA blocker
______________________________________________________________________________________________________
Mifepristone
It is a novel anti-progestin and has anti-glucocorticoid activity without the activity of progesterone, estrogen, androgen and anti-estrogen. It has a progesterone receptor affinity five times as high as progesterone. It is used for anti-pregnancy, inducing menstruation and terminating pregnancy, intrauterine inducer labor for dead fetal.
______________________________________________________________________________________________________
Mifepristone
Oral administration has anti-pregnancy effect, currently applied for people with pregnancy < 49 days. Specific usage in three:
The first usage: orally administration of 600 mg mifepristone in single dose, place 1mg PGF2α (Kaposi prostaglandin) or PGO5 (Kaposi prostaglandin methyl ester) at the vaginal fornix at third or fourth day with the complete abortion rate being as high as 92.3 %. Currently Mifepristone dose has been reduced to a single dose of 200mg, or divided doses of 125-150mg with clinical results not being affected.
The second usage: oral administration of single dose of 600 mg; apply intramuscular injection 0.25 mg of a single oral dose; at 36-48 hours after oral administration, apply intramuscular injection 0.25 mg, or 0.375 mg or 0.5 mg of sulprostone with complete abortion rate of 96%; with the larger amount of sulprostone applied, the sooner the embryonic will be discharged.
The third usage: apply a single oral-administrated dose of 600mg; at 48 hours after oral administration, place 1 mg of ONO802 (gemeprost) pessary suppository inside of the vagina with the complete abortion rate being 95%.
For people with amenorrhea longer than seven weeks, orally administrate 100 mg of mifepristone each time with 2 times per day, and continue for 4 days. You can also apply 1 mg of Kaposi forefront methyl suppository for vagina at 36 to 48 hours after treatment. Have rest in bed for 2 hours and clinic observation for 6 hours. Pay attention to the condition of bleeding after medication to check whether there are pregnancy products being discharged and any adverse reactions.
For labor induction of middle and late dead fetal, take 200 mg each time and 2 times daily. Consecutively take for two days for inducing menstruation and terminating pregnancy. During the 23 to 26 days at menstrual cycle, take 100 ~ 200mg each time with once daily. Consecutively take four days.
______________________________________________________________________________________________________
TRENBOLONE SERIES
Trenbolone CAS: 10161-33-8
Trenbolone Acetate (Finaplix H/Revalor-H) CAS: 10161-34-9
Trenbolone Enanthate (parabolan)
Trenbolone Hexahydrobenzyl Carbonate CAS: 23454-33-3
Metribolone (Methyltrienolone) CAS: 965-93-5
Tibolone CAS: 5630-53-5
Mibolerone CAS: 3704-09-4
Mifepristone CAS: 84371-65-3
______________________________________________________________________________________________________
Main products : Testosterone , Boldenone , Nandrolone , Trenbolone , DECA , Anavar , GHRP-6, MT-2, HGH176-191 , SARMs , GBL , Phenacetin , BB , BA etc.